Study of JNJ-95437446 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer, colorectal cancer, or head and neck squamous cell carcinoma that cannot be removed by surgery or has spread.
- If you have lung or colorectal cancer, your tumor must have been tested for certain gene changes (EGFR for lung, KRAS/NRAS/BRAF for colorectal).
- You must have at least one tumor that can be measured on scans (for the second part of the study).
- You must be able to perform daily activities with little or no help (ECOG 0 or 1).
- Your blood counts, kidney, and liver function must be within acceptable ranges.
- You cannot have had a history of lung inflammation (interstitial lung disease or pneumonitis) that required steroid treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JNJ-89862175 for people with certain advanced solid tumors, including lung adenocarcinoma, kidney cancer, ovarian cancer, and uterine cancer. The goal is to see if this treatment is safe and effective.
This trial tests a new drug, JNJ-87704916, given alone or with other treatments for people with advanced solid tumors that have stopped responding to standard therapies. It may be an option if you have a tumor that can be injected and are in good overall health.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Hear when a new Advanced Stage Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.